The trkA proto-oncogene encodes a high-anity NGF receptor that is essential for the survival, dierentiation and maintenance of many neural and non-neural cell types. Altered expression of the trkA gene or trkA receptor malfunction have been implicated in neurodegeneration, tumor progression and oncogenesis. We have cloned and characterized the 5' region of the mouse trkA gene and have identi®ed its promoter. trkA promoter sequences are GC-rich, lack genuine TATA or CAAT boxes, and are contained within a CpG island which extends over the entire ®rst coding exon. The mouse trkA transcription start site is located 70/71 bp upstream to the AUG translation initiation codon. Sequence analysis showed that the gene encoding the insulin receptor-related receptor, IRR, is located just 1.6 kbp upstream to the trkA gene and is transcribed in the opposite direction. We have used trkA-CAT transcriptional fusions to study trkA promoter function in transient transfection experiments. RNase protection assays and CAT protein ELISA analyses showed that a 150 bp long DNA segment, immediately upstream to the start site, is sucient to direct accurate transcription in trkA-expressing cells. Dissection of this fragment allowed us to identify a 13 bp cis-regulatory element essential for both promoter activity and cell-type speci®c expression. Deletion of this 13 bp segment as well as modi®cation of its sequence by site-directed mutagenesis led to a dramatic decline in promoter activity. Gel mobility shift assays carried out with double-stranded oligonucleotides containing the 13 bp element revealed several speci®c DNA-protein complexes when nuclear extracts from trkA-expressing cells were used. Supershift experiments showed that the Sp1 transcription factor was a component of one of these complexes. Our results identify a minimal trkA gene promoter, located very close to the transcription start site, and de®ne a 13 bp enhancer within this promoter sequence.
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Keywords: trkA; proto-oncogene; promoter; NGF receptor; CpG island; IRR The trkA proto-oncogene was originally isolated from a colon carcinoma as a transforming oncogene activated by a somatic rearrangement that fused a non-muscle tropomyosin gene with the receptor tyrosine kinaseencoding trkA gene (Martin-Zunca et al., 1986 , 1989 . Similar mechanisms are responsible for the malignant activation of trkA in a signi®cant fraction of papillary thyroid carcinomas (Greco et al., 1997) . trkA is the prototype of a family of genes, which includes trkB and trkC, encoding high anity receptors for the neurotrophins of the nerve growth factor family (Barbacid, 1995) . Neurotrophins are responsible for the survival, dierentiation and maintenance of speci®c populations of neurons in the developing and adult nervous system (Davies, 1994) . Expression of trkA is developmentally regulated at the transcriptional level; thus, trkA mRNA ®rst appears at day 9.5 of mouse embryonic development (E9.5) and is restricted to neural crest-derived neurons which are condensing to form sensory ganglia, where trkA expression reaches a maximum at E13.5 (Martin-Zanca et al., 1990) . Expression of trkA in sympathetic neurons starts at E13.5 and reaches highest levels at E18, coinciding with the time of their maximum response to NGF (Ernfors et al., 1992) . In the central nervous system trkA mRNA has been found in NGFresponsive cholinergic neurons of the basal forebrain and neostriatum and in some non-cholinergic neurons in several nuclei at dierent regions of the brainstem (Holtzman et al., 1995) . trkA expressing neurons closely match those that are NGF-dependent for survival and dierentiation, suggesting that trkA could mediate NGF actions in vivo. Consistently, trkA knock-out mice are insensitive to heat and pain, and show extensive loss of small-diameter neurons in the trigeminal (TGG) and dorsal root (DRG) ganglia, which are known to convey nociception and thermoreception stimuli. They are also devoid of sympathetic neurons, and have reduced numbers of cholinergic projections to the hippocampus and cortex (Fagan et al., 1996) . Recently, sensitive in situ hybridization and RNase protection analyses have unveiled widespread expression of trkA in many non-neuronal tissues, including kidney, thymus, testes, stomach and muscle (Lomen-Hoerth and Shooter, 1995; Wheeler et al., 1998) . It has also been shown that NGF-triggered trkA signaling is involved in many autocrine and paracrine circuits playing important roles in the growth, survival and/or dierentiation of dierent cell types, including mast cells and B memory cells (Tam et al., 1997; Torcia et al., 1996 ; skin melanocytes (Yaar et al., 1994) ; and cells from the ovary (Mayerhofer et al., 1996) ; prostate (Dalal et al., 1997) ; and pancreas (Miralles et al., 1998) . Loss of trkA function is responsible for a human disease, congenital insensitivity to pain with anhidrosis (CIPA), characterized by lack of reaction to noxious stimuli (Indo et al., 1996) . In human neuroblastomas, expression of trkA is a good prognostic marker, suggesting that lack of trkA expression contributes to malignancy, perhaps because it results in the loss of signaling pathways important for growth arrest and/or dierentiation of neural crest-derived cells (Brodeur et al., 1997) . Finally, trkA reduced expression has been reported in speci®c cholinergic neuronal populations which are aected in Alzheimer's disease (Boissiere et al., 1997) . The IRR gene encodes a receptor tyrosine kinase, very similar to the insulin receptor, whose pattern of expression is essentially identical to that of trkA. Thus, IRR is co-expressed, at the cellular level, with trkA in sensory and sympathetic ganglia in the peripheral nervous system (Reinhardt et al., 1994) , as well as in some neurons in nuclei of the basal forebrain and brainstem (Tsuji et al., 1996) .
Unveiling the mechanisms controlling trkA gene expression will enhance our understanding on the development and function of the nervous as well as those of other systems, and will shed light into the genesis of some human diseases, including neurodegeneration and cancer. To this end, we have cloned and characterized the promoter region of the mouse trkA gene. A 15 kbp genomic clone, encompassing the 5' region of trkA was isolated from a 129 SvJ mouse library (Figure 1a) . Nucleotide sequence analysis allowed us to identify the ®rst trkA coding exon as well as the ®rst exon of the mouse IRR gene. This gene encodes a receptor tyrosine kinase highly related to the insulin receptor that is transcribed in the opposite Figure 1 Genomic organization of the 5' region of the mouse trkA gene. (a) Physical map of plasmid pDM107, encompassing the ®rst exon of trkA as well as that of the mouse IRR gene (black boxes). pDM107 was derived from a genomic lambda clone isolated from a 129 SvJ mouse library, using a probe corresponding to the 5' end of a previously described mouse trkA clone (Martin-Zanca et al., 1990) . Shadowed boxes indicate the location of putative CpG islands identi®ed by GRAIL: Gene Recognition and Assembly Internet Link (http://compbio.ornl.gov/Grail-1.3). (b) Detailed organization of the 3' region of plasmid pDM107 (B-labeled line in a). Bent arrows indicate the location of the transcription start site of mouse trkA and the putative start site of the IRR gene. Open and ®lled boxes represent non-coding and coding exon sequences, respectively. B1 repetitive sequences are shown as crosshatched boxes. pDM87 is a plasmid used for S1 nuclease mapping of the trkA 5' end. (c) Structure of the CpG island encompassing the ®rst exon of mouse trkA. Nucleotides are numbered with respect to the trkA start of transcription (bent arrow, +1). High de®nition mapping of cytosine methylation of a 1078 bp DNA fragment encompassing the ®rst exon (7444 to +633) was carried out as described by Frommer and colleagues (Clark et al., 1994) . The distribution of the CG dinucleotides as well as their methylation status is shown. Open circles represent CpGs that are not methylated in mouse liver DNA; ®lled circles indicate the two CpGs that are methylated direction to that of trkA, from the complementary DNA strand (Figure 1b) . The transcription start site of the mouse IRR gene has not been reported; however, a putative TATA box, located 29 bp upstream to the start site of the rat gene, is conserved in the mouse gene, suggesting that the position of the start of transcription may be also conserved (Shier and Watt, 1992) . The nucleotide sequence around the ®rst coding exon of trkA is very GC-rich, suggesting that it may correspond to a CpG island (Bird, 1986) . Sequence analysis using GRAIL (Gene Recognition and Assembly Internet Link) revealed that a 443 bp island, with a GC content of 73.38% and a ratio of observed/expected CpGs of 0.81, covers the ®rst exon of trkA and extends some 190 bp upstream to the AUG translation initiation codon. Methylation analyses carried out using methylation-sensitive restriction enzymes showed that the CpG pairs contained within the SacII, NruI, BssHII and EagI recognition sites ( Figure 1c) were not methylated in DNA from mouse tissues such as liver, which does not express trkA (not shown). High de®nition mapping of cytosine methylation, carried out following the procedure described by Frommer and colleagues (Clark et al., 1994) , showed that, of the 69 CG dinucleotides included in a 1078 bp region around the ®rst trkA exon, only two CG pairs located at the 3' end of this region are methylated in liver DNA (Figure 1c ). These results con®rmed that the ®rst coding exon of mouse trkA is contained within a CpG island. GRAIL analysis of the 5' end of human trkA showed that it is also included in a putative CpG island, 563 bp long, with a GC content of 66.53% and a CpG score of 0.68 (not shown). Interestingly, a short cluster of CG dinucleotides within the 5' end of the mouse IRR gene was identi®ed by GRAIL as a 211 bp CpG island, with a GC content of 69.55% and a CpG score of 0.72 ( Figure 1a ).
Previous in situ hybridization analyses had shown that trkA is expressed in neural crest-derived sensory and sympathetic ganglia during mouse embryonic development. In this study we have analysed the expression of trkA by Northern blot using total RNA from kidney, spinal cord, and isolated DRG and TGG from E15 ± 17 mouse embryos. As shown in Figure 2a , high levels of a 3.0 kbp trkA-speci®c mRNA were detected in DRG and TGG; lower expression levels were observed in spinal cord, while no expression was detected in kidney. The transcription start site of the mouse trkA gene was identi®ed by a combination of primer extension and S1 nuclease protection analyses, using RNA from isolated DRG of E15 ± 17 mouse embryos. As shown in Figure 2b , the extended cDNA products, 152 and 153 nucleotides in length, comigrated with the S1 digestion-protected fragments, thus locating the start of transcription of the mouse trkA gene at a CG dinucleotide, 71/70 nucleotides upstream to the AUG translation initiation codon, and showing that the ®rst exon of the gene includes the AUG. The start of transcription of mouse trkA is just 1.6 kbp away from the putative start site of the IRR gene (Figure 1b) .
To identify trkA genomic sequences containing promoter activity, transcriptional fusions between trkA and the bacterial chloramphenicol acetyl transferase (CAT) gene were generated and used in transient transfection assays on two cell lines which express trkA, N2a and PC12, as well as in the human epithelial cell line 293 which does not express trkA. Reporter gene expression was monitored by RNase protection or by Figure 2 Identi®cation of the transcription start site of the mouse trkA gene. (a) Northern blot analysis. 10 mg of total RNA were hybridized to a random primed 32 P-labeled 850 bp fragment corresponding to the 5' region of a mouse trkA cDNA, as described (Martin-Zanca et al., 1990) . DRG and TGG: dorsal root and trigeminal ganglia from E15 ± 17 mouse embryos; K: kidney; SC: spinal cord; PC12: rat pheochromocytoma cell line; N2a; mouse neuroblastoma cell line; NCB20: mouse neuroblastoma-hamster neuron hybrid. (b) Primer extension and S1 nuclease digestion analyses of 20 mg of RNA from mouse embryonic DRG. For primer extension, a 5'-end-labeled oligonucleotide (N29: 5'-AGCATCAACGAAGTCATCAGAC-TGCCTAGC-3'), complementary to the mouse trkA sequence between nucleotides +52 and +82, relative to the AUG codon, was used. For S1 nuclease digestion, a 300 nt long 5'-end-labeled, single-stranded DNA probe was generated using 5'-end-labeled N29 as primer and plasmid pDM87 (Figure 1b) as template. Primer extension and S1 nuclease digestion analyses were performed according to published protocols (Sambrook et al., 1989) . Reaction products (lanes P.e. and S1) were resolved on a 6% denaturing poliacrylamide gel, along a DNA sequencing ladder obtained from the pDM87 clone using the N29 oligonucleotide. 5'-P*: 5'-end-labeled N29 primer; S1: singlestranded 5'-end-labeled probe CAT protein determination. Transient transfection analyses showed that a DNA fragment extending 1.8 kbp upstream of the trkA transcription start site exhibited promoter activity in N2a and PC12 cells but not in the 293 cell line. In order to de®ne a smaller region capable of directing reporter expression in N2a and PC12 cells, a series of progressive 5' deletions were derived from pMS8 ( Figure 3a) . As shown in Figure 3b , all deletion constructs, except pMS22, which extends only 43 nucleotides upstream to the transcription start site, directed accurate transcription initiation in these cells, as evidenced by the protection of a 224 nt fragment corresponding to the 5' end of the trkA-CAT chimeric mRNAs (Figure 3b, lanes 3 ± 15) . No such protection was observed in untransfected cells or in cells transfected with control pUC-CAT plasmid Figure 3 Functional characterization of the mouse trkA gene promoter. (a and d) trkA-CAT transcriptional fusions made on a promoter-less vector, pUC-CAT, containing four copies of the polyadenilation signal of SV40 upstream to the polylinker. pMS8 contains 1.8 kbp of trkA sequences extending from the SalI site (at 71759) to the AUG codon (at +71). Progressive deletions from the 5' end of this trkA fragment were generated by Exonuclease III or PstI (pMS16) digestions. Shorter deletions (d) were generated by PCR. pMS31 contains the sequence 756 to 768 in the reverse orientation (underlined). Base substitutions in pMS34 (asterisks) were introduced according to the QuikChange Site-directed mutagenesis Kit protocol (Stratagene, La Jolla, CA, USA). Horizontal arrows indicate an inverted repeat. trkA-CAT plasmids (10 mg) and plasmid CMV-lacZ (1 mg), were co-transfected into N2a, PC12 or 293 cells by the calcium-phosphate method (Sambrook et al., 1989) . After 40 h, reporter gene expression was determined by RNase protection assay or by measuring CAT protein levels using a CAT-ELISA kit (Boehringer Mannheim, Mannheim, Germany). In parallel, cell extracts were used to quantify b-galactosidase activity (Sambrook et al., 1989) . (b) Representative RNase protection analysis of N2a transfected cells using a 397 nt riboprobe capable of identifying the 5' end of the chimeric trkA-CAT mRNA. This fragment contains 153 nt complementary to the 5' end of the CAT gene and 71 nt complementary to trkA transcript sequences, 5' to the AUG codon. To identify the lacZ transcript, a 309 nt riboprobe containing 192 nt complementary to the 5' end of the lacZ gene was used. 10 mg of total RNA were hybridized simultaneously to the two riboprobes and processed following standard protocols (Ausubel et al., 1995) . Lanes 3 ± 15 show a 224 nt protected fragment, speci®c for the 5' end of the trkA-CAT fusion mRNA. The 192 nt protected fragment indicates expression of the CMV-lacZ internal control (lanes 2 ± 16). (c) Relative CAT protein levels normalized with respect to b-galactosidase activity. CAT values (mean+s.e., n=3 ± 5, duplicated experiments) are given as percentages relative to the promoter activity of plasmid pMS14.10 (100%). (e) Histogram showing normalized CAT protein levels. CAT values (mean+s.e., n=2 ± 8, duplicated experiments) are given as percentages relative to the promoter activity of plasmid pMS16 (100%) (Figure 3b, lanes 1 and 2) . Similar results were obtained when the deletion constructs were transfected into the PC12 cell line; in contrast, none of the trkACAT fusions exhibited promoter activity when transfected into the 293 cell line (not shown). Quantitative analyses of the promoter activity obtained by CAT protein determination, showed that all deletions, except for pMS22, exhibited signi®cant levels of promoter activity in N2a cells (Figure 3c ). These results indicated that a small region of 150 nt, 5' to the trkA transcription start site, was capable of directing accurate, cell type-speci®c transcription, to levels comparable to those of fusions extending further upstream in trkA, indicating that cis elements responsible for cell type-speci®c transcription were located between nucleotides 7150 and 743. To identify this essential cis element we dissected this region by generating four additional plasmids, pMS21, pMS28, pMS29 and pMS30 which extended 93, 68, 63 and 56 nucleotides upstream of the transcription start site of trkA, respectively (Figure 3d ). Transient transfection assays showed that pMS21 and pMS28, extending to 793 and 798, exhibited 90 and 50% of the promoter activity of pMS16, respectively. However, removing ®ve or 13 nucleotides at the 5' end of pMS28, drastically reduced promoter activity, being the levels of CAT protein produced by pMS29 and pMS30 similar to those obtained with pMS22, a plasmid essentially incapable of directing accurate transcription as determined by RNase protection (Figure 3e ). These results suggested that the 13 nucleotides between 768 and 756 (GGGCGGGGCCGTG) were important for promoter activity. This segment contains a 9 bp sequence with dyad symmetry (GGC GGG GCC) which seemed a good candidate for a cis-regulatory element that could function in either the direct or the reverse orientation. To test this hypothesis, the sequence complementary to nucleotides 768 to 756 was inserted at the 5' end of plasmid pMS30, which extends to 756, generating plasmid pMS31 ( Figure  3d ). This resulted in the recovery of promoter activity to a level similar to that of pMS28 (Figure 3e) . In order to analyse the sequence requirements of this cis element to drive transcription, three base pair substitutions, which destroyed the dyad symmetry, were introduced into the pMS16 backbone generating plasmid pMS34 (Figure 3d ). As shown in Figure 3e , pMS34 exhibited a very low level of promoter activity in comparison to that of the parental pMS16 plasmid, suggesting that a cis element contained within this small GC-rich trkA sequence is required for cellspeci®c transcription of the trkA-CAT reporter fusions. In addition, this cis-regulatory element can function in both orientations, thus behaving as an enhancer that could bind trans acting nuclear factors. To test this hypothesis, electrophoretic gel mobility shift assays (EMSA) were performed using as a probe a 19-mer double-stranded oligonucleotide whose sequence (5'-GCGGGGCGGGGCCGTGGGT-3') corresponds to that of the 771 to 753 trkA segment, and includes the 13 bp element identi®ed as essential for transcription. As shown in Figure 4a , three DNA-protein complexes, I, II and III, were obtained using nuclear extracts from N2a cells (lane 2). These three complexes were competed speci®cally by the unlabeled oligonucleotide probe used at 50-fold molar excess (S, lane 3), whereas none of these complexes were competed by a 50-fold molar excess of an unrelated 19-mer oligonucleotide (NS, lane 4), nor by a 19-mer oligonucleotide containing three base pair substitutions that destroyed the inverted repeat sequence motif (M, lane 5). Moreover, no DNA-protein complexes were formed when the mutated oligonucleotide was used as a probe (Figure 4b) . These results demonstrated the binding of speci®c proteins, present in N2a nuclear extracts, to the 771/753 sequence. Nuclear extracts prepared from PC12 and NCB20, two cell lines which express trkA, yielded similar retardation patterns to those obtained with N2a extracts (not shown). In contrast, complexes I, II and III were essentially undetectable in the nonexpressing 293 cell line; although a dierent nonspeci®c complex was observed in these cells (Figure 4a , lanes 6 ± 8; b, lanes 4 ± 5). These data suggest that speci®c DNA-binding proteins interact with cis elements within the 771/753 region, and that these proteins are probably involved in mediating cellspeci®c trkA expression. Interestingly, the use of excess amounts of non-speci®c oligonucleotides seems to favor the formation of the three speci®c complexes in N2a cells, and allows for their detection in 293 cells (Figure 4a , lanes 4, 5 and 8). Analysis of the 150 nucleotides upstream to the transcription initiation site using TESS, revealed the presence of multiple GC-rich Figure 4 Trans-acting factors present in trkA-expressing cell lines bind to the 771/753 trkA sequence. Electrophoresis gel mobility shift assay (EMSA) using the double-stranded 19-mer oligonucleotide 771/753 (a) or a 771/753 mutated oligonucleotide (b) as probes and nuclear extracts from trkA-expressing N2a cells and trkA-negative 293 cells. The three DNA-protein complexes I, II and III detected in N2a cells (lanes 2, 4 and 5 of panel a) are indicated. EMSA was performed according to described protocols (Ausubel et al., 1995) , using 10 mg of nuclear protein extracts, prepared from subcon¯uent cell cultures, and 0.5 ± 1 ng of 32 P-labeled double-stranded oligonucleotides. The sequences of the upper strands of each of the probes used were, 771/753:
5'-GCGGGGCGGGGCCGTGGGT-3'; mutated 771/753: 5'-GCGGATCGGGGTCGTGGGT-3'; and non-speci®c oligonucleotide: 5'-ATATTCTGAGACAGCCTTC-3'. 7In-dicates absence of competitor oligonucleotide. 50-fold molar excess of unlabeled competitors were added as follows, S: speci®c oligonucleotide probe; NS: non-speci®c, i.e. unrelated, oligonucleotide; M: mutated oligonucleotide consensus sequences for transcription factors; in particular the segment between 793 and 756 contains three potential binding sites for Sp1, two for AP-2, and several for GCF (Figure 5a ). Most of these sites are conserved in the promoter region of human trkA (Chang et al., 1998) . The 771/753 oligonucleotide contains consensus binding sites for Sp1, AP-2 and, with a single mismatch, for Egr-1. For this reason, antibodies speci®c for Sp1, Egr-1 and AP-2 proteins were used to test whether any of these factors were components of complexes I, II or III. As shown in Figure 5b , in the presence of a speci®c anti-Sp1 antibody the slower-migrating complex (I) changed its mobility and was further retarded, i.e. was supershifted, indicating that the Sp1 protein participates in this complex. The slight reduction in the intensity of complexes I, II and III observed in the presence of anti-Egr-1 and anti-AP2 antibodies may be due to nonspeci®c interference of the antibodies with complex formation; however, neither anti-AP2 nor anti-Egr-1 antibodies supershifted any of these complexes, suggesting that neither factor is present in them.
The function of the NGF receptor, trkA, is controlled at dierent levels, an important one being the transcriptional regulation during development and in the adult life. Therefore, alterations of trkA transcription may underlie disorders such as neurodegeneration and tumor progression. In this report we have described the structure of the mouse trkA promoter, and the identi®cation of cis-regulatory sequences that are essential for cell type-speci®c transcription of trkAreporter gene fusions, and are capable of binding nuclear factors present in trkA-expressing cells. We have located the transcription start site just 70/71 nucleotides upstream to the AUG translation initiation codon, in a very GC-rich region, devoid of TATA, CAAT or initiator sequences. In spite of this, the start of transcription is unique, and lies 20 nucleotides downstream to a potential Sp1 binding site. In contrast, the human trkA gene seems to initiate transcription at several sites, all close to the AUG codon. The reason for this dierence is not clear; however, it is possible that dierent transcription start sites are used in dierent cell types; thus, we have de®ned the mouse trkA start site in RNA from primary embryonic DRGs, while that of the human gene was determined in transformed cell lines (Chang et al., 1998) .
A CpG island of unmethylated DNA encompasses the 5' region of the mouse trkA gene, raising the possibility that methylation plays a role in regulating trkA expression. Methylation of the trkA island may suppress trkA expression, which in turn could result in the loss of NGF-dependent neuronal populations, leading to neurodegeneration. In fact, lack of trkA expression has been observed in speci®c neuronal populations of Alzheimer's disease patients (Bossiere et al., 1997) , although the cause of this de®cit is unknown. In the other hand, loss of trkA expression may be involved in neuroblastoma progression (Brodeur et al., 1997) . Analysis of the 5' region of mouse trkA revealed the close presence of the IRR gene, encoding a receptor tyrosine kinase, which is transcribed in the opposite direction, from the complementary DNA strand. The putative start of transcription of the mouse IRR gene is located just 1.6 kbp away from that of the trkA gene. It is unlikely that trkA and IRR are driven by a bi-directional promoter; however, they are co-expressed at the cellular level in both neuronal and non-neuronal tissues in rat (Reinhardt et al., 1994; Tsuji et al., 1996) , suggesting that they may share regulatory elements acting both in cis and in trans. Similar genomic arrangements may exist in other species; thus, both the IRR and trkA genes are located in human chromosome 1 (Shier et al., 1990; Valent et al., 1997) . We have shown that a small region of 150 nucleotides, 5' to the mouse trkA gene, is required for promoter activity and for cell-type speci®c transcription. Detailed analyses of this region allowed us to identify a 13 bp cis-regulatory element that behaves as a tissue-speci®c enhancer. This element contains a 9 bp sequence with dyad symmetry composed of a three nucleotide inverted repeat separated by a stretch of three G residues (767: GGC GGG GCC). Disruption of this sequence or mutations that destroyed the dyad symmetry drastically reduced transcription activity to levels similar to those of inactive fusions. A similar motif is conserved at an equivalent position in the human trkA promoter, although in this case there are four G residues separating the three-nucleotide inverted repeat (Chang et al., 1998) . This mouse trkA cisregulatory element was capable of binding nuclear Gel mobility shift assays performed using N2a nuclear extracts and the 771/753 double-stranded oligonucleotide as probe, in the presence or absence of 2 mg of anti-Sp1, anti-AP2 or anti-Egr1 antibodies (Santa Cruz Biotechnology, Santa Cruz, CA, USA). Antibodies were added to the reaction mixture and incubated for 1 ± 2 h on ice before adding the labeled probe. I, II and III indicate DNA-protein complexes; SS indicates a supershifted complex formed in the presence of anti-Sp1 antibody proteins present in trkA-expressing cell lines, giving rise to three speci®c DNA/protein complexes, which resembled those observed in human neuroblastoma cell lines, using a longer human DNA probe (Chang et al., 1998) . These complexes were undetectable in trkA non-expressing cell lines, suggesting that the nuclear factors involved in their formation may contribute to the tissue-speci®c expression of trkA. However, these factors may be present, at low levels, in 293 cells being only apparent in the presence of large concentrations of non-speci®c competitors. An oligonucleotide containing a triple mutation that destroyed the dyad symmetry did not bind nuclear factors nor did it compete with the wild type oligonucleotide for complex formation, suggesting that the inverted repeat element is required both for transcription in transfection experiments in N2a cells, and for DNA-protein complex formation in vitro. This DNA segment contains potential binding sites for several factors, including Sp1, MAZ, GCF and AP-2. Sp1 and MAZ are general transcription activators that have been proposed as important regulators of TATA-less promoters (Parks and Shenk, 1996) , whereas GCF acts as a repressor for GC-rich promoters (Kageyama and Pastan, 1989) ; in the other hand, AP-2 is a speci®c transcriptional activator present in neural crest-derived lineages (Mitchell et al., 1991) . Thus, both positive and negative transcription factors as well as general and speci®c ones, can potentially interact with the cisregulatory element at the trkA promoter in order to regulate its expression (Figure 5a ). An anti-Sp1 antibody speci®cally recognized a component of complex I as evidenced by the slower migration of this complex in supershift experiments; in contrast, AP-2 and Egr-1 antibodies failed to supershift any of those three DNA-protein complexes. Sp1 by itself may not account for cell-type speci®c transcription but it may cooperate with other factors to regulate the trkA promoter. Dierent sets of factors are probably involved in the formation of complexes II and III and it is likely that precise regulation of trkA expression is dependent on the interaction of multiple transcription factors both at the cis element described in this report, as well as in other regions of the gene. Further studies are required to identify them.
